Sensitivity analyses for effect modifiers not observed in the target population when generalizing treatment effects from a randomized controlled trial: Assumptions, models, effect scales, data scenarios, and implementation details

Background Randomized controlled trials are often used to inform policy and practice for broad populations. The average treatment effect (ATE) for a target population, however, may be different from the ATE observed in a trial if there are effect modifiers whose distribution in the target population is different that from that in the trial. Methods exist to use trial data to estimate the target population ATE, provided the distributions of treatment effect modifiers are observed in both the trial and target population—an assumption that may not hold in practice. Methods The proposed sensitivity analyses address the situation where a treatment effect modifier is observed in the trial but not the target population. These methods are based on an outcome model or the combination of such a model and weighting adjustment for observed differences between the trial sample and target population. They accommodate several types of outcome models: linear models (including single time outcome and pre- and post-treatment outcomes) for additive effects, and models with log or logit link for multiplicative effects. We clarify the methods’ assumptions and provide detailed implementation instructions. Illustration We illustrate the methods using an example generalizing the effects of an HIV treatment regimen from a randomized trial to a relevant target population. Conclusion These methods allow researchers and decision-makers to have more appropriate confidence when drawing conclusions about target population effects.

[1]  M A Fischl,et al.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. , 1997, The New England journal of medicine.

[2]  Geoffrey D. Borman,et al.  Site Selection in Experiments: An Assessment of Site Recruitment and Generalizability in Two Scale-up Studies , 2016 .

[3]  Howard S. Bloom,et al.  A Conceptual Framework for Studying the Sources of Variation in Program Effects , 2013 .

[4]  S. Schneeweiss,et al.  From Trial to Target Populations - Calibrating Real-World Data. , 2017, The New England journal of medicine.

[5]  Lisa M. Lee,et al.  Estimation of HIV incidence in the United States. , 2008, JAMA.

[6]  Eloise E Kaizar,et al.  The use of propensity scores and observational data to estimate randomized controlled trial generalizability bias , 2013, Statistics in medicine.

[7]  S. Cole,et al.  Correction: Sensitivity analysis for an unobserved moderator in RCT-to-target-population generalization of treatment effects , 2016, The Annals of Applied Statistics.

[8]  Michael J. Weiss,et al.  A CONCEPTUAL FRAMEWORK FOR STUDYING THE SOURCES OF VARIATION IN PROGRAM EFFECTS: Sources of Variation in Program Effects , 2014 .

[9]  Eloise E Kaizar Estimating treatment effect via simple cross design synthesis , 2011, Statistics in medicine.

[10]  Michael G Hudgens,et al.  Generalizing Study Results: A Potential Outcomes Perspective. , 2017, Epidemiology.

[11]  J. Ware,et al.  Detecting Moderator Effects Using Subgroup Analyses , 2013, Prevention Science.

[12]  E. Stuart,et al.  Generalizing Treatment Effect Estimates From Sample to Population: A Case Study in the Difficulties of Finding Sufficient Data , 2017, Evaluation review.

[13]  Elizabeth Tipton Improving Generalizations From Experiments Using Propensity Score Subclassification , 2013 .

[14]  Ravi Varadhan,et al.  A framework for the analysis of heterogeneity of treatment effect in patient-centered outcomes research. , 2013, Journal of clinical epidemiology.

[15]  D. Rubin Estimating causal effects of treatments in randomized and nonrandomized studies. , 1974 .

[16]  Alex H. S. Harris,et al.  Influence of subject eligibility criteria on compliance with National Institutes of Health guidelines for inclusion of women, minorities, and children in treatment research. , 2007, Alcoholism, clinical and experimental research.

[17]  Stephen R Cole,et al.  Transportability of Trial Results Using Inverse Odds of Sampling Weights. , 2017, American journal of epidemiology.

[18]  Catherine P. Bradshaw,et al.  Assessing the Generalizability of Randomized Trial Results to Target Populations , 2015, Prevention Science.

[19]  Jennifer Hill,et al.  Assessing Methods for Generalizing Experimental Impact Estimates to Target Populations , 2016, Journal of research on educational effectiveness.

[20]  David M Kent,et al.  Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal , 2010, Trials.

[21]  S. Cole,et al.  Generalizing evidence from randomized clinical trials to target populations: The ACTG 320 trial. , 2010, American journal of epidemiology.

[22]  S. Cole,et al.  Causal Impact: Epidemiological Approaches for a Public Health of Consequence. , 2016, American journal of public health.